Abstract-Pressure overload ventricular hypertrophy is accompanied by dysfunctional ␤-adrenergic receptor signaling due to increased levels of the ␤-adrenergic receptor kinase-1, which phosphorylates and desensitizes ␤-adrenergic receptors.
C ardiac hypertrophy is an adaptive condition frequently associated with impairment of contractility, often leading to heart failure. 1, 2 The mechanisms involved in this transition are not known; however, one mechanism appears to be impaired signaling through myocardial ␤-adrenergic receptors (␤ARs). 3 We recently demonstrated that dysfunctional ␤AR signaling associated with pressure overload ventricular hypertrophy is caused by enhanced expression and activity of the ␤AR kinase (␤ARK1), which phosphorylates agonist-occupied ␤ARs leading to desensitization. 4 ␤ARK1, a member of the G protein-coupled receptor kinase (GRK) family, appears to be a critical modulator of in vivo myocardial function. We have shown that increased expression of ␤ARK1 in the hearts of transgenic mice leads to blunting of ␤AR inotropic responses, 5 whereas selective decreases of ␤ARK1 activity 5 or expression 6 in the heart result in enhanced myocardial performance. Moreover, adding to the importance of ␤ARK1 are the findings that this GRK is increased in several cardiovascular disorders besides hypertrophy, such as myocardial ischemia, 7 hypertension, 8 and heart failure. 9 Increased sympathetic nervous system (SNS) activity is a feature of all the above-mentioned conditions including hypertrophy in which ␤ARK1 is increased. 10, 11 The sympathetic catecholamines norepinephrine and epinephrine can interact with both ␣ 1 -and ␤ARs present on the sarcolemmal membranes of cardiomyocytes leading to the activation of differential intracellular signaling pathways. 12, 13 Stimulation of either ␤ARs or ␣ 1 ARs can lead to myocardial hypertrophic responses. 14 The object of the present study was to test whether cardiac adrenergic activation is responsible for the increase in ␤ARK1 levels during hypertrophy and to investigate the relative role of cardiac ␣ 1 -and ␤ARs. Cardiac hypertrophy was induced in mice by chronic administration of the ␤-agonist isoproterenol (ISO) or the ␣ 1 -agonist phenylephrine (PE). We also studied a transgenic model of direct myocardial ␣ 1 AR-induced cardiac hypertrophy 15 and agonist-treated cultured adult rat ventricular myocytes.
Methods
Animals, Study Design, and Pump Implantation C57/Bl6 mice weighing 25 to 30 g were used. The institutional animal usage committee at Duke University Medical Center approved all animal procedures. Miniosmotic pumps (Alzet model 2002) were implanted in mice anesthetized with ketamine (10 mg/kg) and xylazine (0.5 mg/kg). 16 Pumps were filled with ISO, PE, or vehicle (0.02% ascorbic acid) and were set to deliver ISO at 30 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 and PE at 100 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 for 14 days each. After treatment, animals were weighed and anesthetized, and their hearts were excised, rinsed, and blotted dry. The isolated hearts were then weighed and frozen in liquid nitrogen and stored at Ϫ70°C until studied. The heart weight-to-body weight ratio was then calculated (milligrams/gram).
Ventricular Myocyte Cross-Sectional Area
After treatment, 3 animals from each group were anesthetized as above, and the hearts were perfusion fixed. A plastic cannula was placed in the aortic root, and the hearts were perfused at the constant pressure of 70 mm Hg through the coronary circulation with ice-cold PBS for 30 minutes, and then fixed through the same route with buffered 1% formaldehyde solution for 30 minutes. Hearts were then cut along a midsagittal plane, paraffin embedded, and sectioned. Sections were then labeled with fluorescein-conjugated wheat germ agglutinin as described, 15 video micrographs of sections were taken by use of systematic sampling, and cross-sectional areas of myocytes were measured by use of NIH-Image 1.63 software. The crosssectional areas of 100 left ventricular (LV) free wall myocytes were determined from each heart studied. 5, 16 All assays were performed in triplicate, and receptor density (femtomoles) was normalized to milligrams of membrane protein.
␤AR Radioligand Binding

Adenylyl Cyclase Activity
Crude myocardial membranes were prepared as described above. Membranes (20 to 30 g of protein) were incubated for 15 minutes at 37°C with [␣-32 P]ATP under basal conditions or in the presence of either 0.1 mmol/L ISO or 10 mmol/L NaF, and cAMP was quantitated by standard methods as described. 5, 16 
Protein Immunoblotting
Immunodetection of myocardial levels of ␤ARK1 was performed on detergent-solubilized extracts after immunoprecipitation, as we described previously. 4, 16 Excised hearts were homogenized and ␤ARK1 was immunoprecipitated from 1 mL of clarified extract (equal protein amounts) with 1:2000 (0.5 L) monoclonal ␤ARK1 antibody 4, 16 and 35 L of a 50% slurry of protein A-agarose conjugate agitated for 1 hour at 4°C. Immune complexes were then washed, electrophoresed through 12% polyacrylamide Tris/glycine gels, and transferred to nitrocellulose. 4, 16 The 80-kDa ␤ARK1 protein then was visualized with the same monoclonal antibody and chemiluminescence detection (ECL, Amersham). Immunodetection of myocardial levels of GRK5 and G␣i was performed in myocardial membranes as described. 4, 16 GRK5 was visualized with a monoclonal antibody raised to the carboxyl terminus of GRK5, 16 and G␣i was visualized with a commercially available polyclonal antibody to G␣i 1-3 (Santa-Cruz). Quantitation of immunoreactive ␤ARK1, GRK5, and G␣i was done by scanning the autoradiography film and with use of ImageQuant software (Molecular Dynamics).
GRK Activity Assay
Cytosolic myocardial extracts were prepared by homogenization of excised hearts in 2 mL of ice-cold lysis buffer [25 mmol/L Tris-Cl (pH 7.5), 5 mmol/L EDTA, 5 mmol/L EGTA, 0.002 mmol/L leupeptin, 0.003 mmol/L aprotinin, and 1 mmol/L PMSF] as we described previously. 4, 5, 16 Cytosolic protein (100 to 150 g) was incubated with rhodopsin-enriched rod outer segment (ROS) membranes in lysis buffer with 10 mmol/L MgCl 2 and 0.1 mmol/L ATP (containing [␥-32 P]ATP). After incubation with white light for 15 minutes at room temperature, the reaction was quenched with ice-cold lysis buffer and centrifuged for 15 minutes at 13 000g. The pelleted material was electrophoresed through 4% to 20% polyacrylamide Tris/glycine gels, and phosphorylated rhodopsin was visualized by autoradiography of dried gels and quantified with a Molecular Dynamics PhosphorImager. 4, 5, 16 
Cultured Adult Rat Ventricular Myocytes
Sprague Dawley rats were anesthetized and heparinized, and the hearts were explanted and rinsed in cold PBS. Isolated rat hearts were then perfused with Joklik's modified minimum medium containing hyaluronidase, collagenase, bacterial protease, and 0.0125 mmol/L CaCl 2 and myocytes cultured as we described previously. 17 Myocytes were plated at equal density in M199 in the presence of 10% fetal bovine serum (FBS) on 150-mm tissue culture plates precoated with 20 g/mL of mouse laminin. 17 After 2 hours to allow rod-shaped myocytes to attach to the culture plate, cells were incubated with ISO (10 Ϫ6 mol/L) or PE (10 Ϫ6 mol/L) in the presence of 1% FBS. Fresh agonists were added to the medium after 12 hours. After 24 hours, the medium was removed, the cells were rinsed, and ␤ARK1 was immunoprecipitated as described above.
Statistical Analysis
Data are expressed as meanϮstandard error. Statistical comparisons were performed by ANOVA, followed by Bonferroni post hoc analysis.
Results
Heart Weight-to-Body Weight Ratios and Histological Measurements
Chronic PE or ISO infusion resulted in similar increases in the heart weight-to-body weight ratio compared with the control vehicle-treated animals ( Figure 1A) . Consistent with the increased cardiac mass and hypertrophy, cross-sectional areas of myocytes from ISO-and PE-treated hearts were increased ( Figure 1B) .
␤AR Density and Signaling
The effects of chronic exposure to PE and ISO on cardiac ␤AR signaling were assessed by measuring myocardial ␤AR density and functional coupling to membrane adenylyl cyclase activity. As expected, chronic exposure to ISO resulted in a decrease in ␤AR density in the heart which was ϳ50% (Table) . In contrast, PE did not induce any change in ␤AR density (Table) . Adenylyl cyclase activity in cardiac membranes was impaired in the ISO group both basally and after ISO stimulation (Table) . Absolute amounts of cAMP production in PE-treated animals also were decreased (Table) , but ␤AR responsiveness to ISO was significantly greater than in ISO-treated cardiac membranes (Table) . This was calculated as the percent increase in adenylyl cyclase activity over baseline induced by ISO. In membranes from PE-treated hearts, ISO induced a 52Ϯ3% increase in cyclase activity over the basal value, which was similar to the control response (45Ϯ2%). ␤AR responsiveness was significantly reduced in membranes purified from ISO-treated mice (22Ϯ3%, PϽ0.05 versus control), indicating that chronic exposure to ISO results in ␤AR desensitization. In all groups, stimulation of adenylyl cyclase activity by NaF was similar (Table) , suggesting there were no treatment-induced changes in adenylyl cyclase itself.
Cardiac ␤ARK1, GRK5, and G␣i Expression and Activity
To assess the possible involvement of ␤ARK1 in uncoupled ␤AR signaling, we examined ␤ARK1 levels in control, ISO-, and PE-treated hearts. As shown in Figure 2A , ␤ARK1 was significantly elevated in hearts treated with ISO but not PE, which corresponded to enhanced cytosolic GRK activity ( Figure 2B ). To rule out the involvement of other GRKs in this result, we examined the levels of GRK5, a second GRK expressed in the heart that can act on ␤ARs. 18 In contrast to the results with ␤ARK1, no differences in myocardial GRK5 expression were seen in any of the hearts (data not shown).
Because our results with ␤ARK1 suggested differential regulation by ISO-and PE-induced treatment, we examined a second model of ␣ 1 AR-mediated myocardial hypertrophy. This is a transgenic mouse with myocardial-targeted overexpression of a constitutively activated mutant (CAM) ␣ 1B AR. This mouse develops myocardial hypertrophy because of enhanced signaling through the CAM-␣ 1B ARs. 15 ␤ARK1 content in these CAM-␣ 1B AR hearts was similar to ␤ARK1 content in their nontransgenic littermates (Figure 3) confirming the inability of ␣ 1 -adrenergic signaling to regulate myocardial ␤ARK1 levels. This also demonstrated that increases in ␤ARK1 expression are not associated with this model of myocardial hypertrophy.
Because the different patterns of alteration in ␤ARK1 content in ISO-and PE-treated mice could be caused by differences induced by these two agents in peripheral and central hemodynamics, we examined the regulation of ␤ARK1 in cultured adult rat ventricular myocytes. Cells were exposed for 24 hours to either ISO or PE, and ␤ARK1 levels were assessed. In this model, the effects on ␤ARK1 expression were apparently due to the direct activation of myocardial ␤ARs as ISO significantly enhanced ␤ARK1 content, whereas PE did not alter ␤ARK1 expression (Figure 4) .
Our results fit with the hypothesis of a specific impairment of ␤AR signaling induced by chronic activation of cardiac ␤ARs but not ␣ 1 ARs. Nevertheless, in PE-treated animals we found a reduction in basal adenylyl cyclase activity (Table) . To explore a possible mechanism to explain this alteration, we assessed G␣i level in PE-treated mouse hearts. We found that in PE-treated hearts the content of G␣i was significantly increased by 50% ( Figure 5 ). ISO did not induce this increase (data not shown). Thus, reduced adenylyl cyclase activity in PE-treated hearts may be explained by enhanced Gi levels. 
Discussion
Chronic treatment of mice with PE and ISO resulted in similar cardiac hypertrophic responses, which were manifest as increased myocardial mass and size of ventricular myocytes. Although myocardial hypertrophy was induced by both treatments, only ISO induced changes in myocardial GRK activity that were due to enhanced levels of ␤ARK1. Previously, we showed that chronic treatment with ISO can lead to increased expression of ␤ARK1 in the heart, which in turn impairs ␤AR signaling 16 ; however, PE-induced hypertrophy is not associated with a similar enhancement of ␤ARK1 expression, which demonstrates a differential regulation of ␤ARK1 in response to SNS activity. Thus, ␤AR but not ␣ 1 AR stimulation selectively regulates myocardial ␤ARK1 expression. Increased expression of ␤ARK1 can have detrimental effects on myocardial ␤AR signaling and function, and enhanced ␤ARK1 actually appears to be an early defect in ventricular hypertrophy induced by pressure overload. 4 The increased ␤ARK1 found in pressure overload hypertrophy is likely responsible for impaired ␤AR contractile responses, because pressure overload in transgenic mice expressing a ␤ARK1 inhibitor does not lead to impaired in vivo cardiac function. 4 The mechanisms that underlie increases in myocardial ␤ARK1 in pressure overload hypertrophy are not clear, but catecholamines resulting from enhanced SNS activity are elevated in hypertrophy. It is likely that the chronic adrenergic activation by endogenous catecholamines can sustain the increase in cardiac ␤ARK1 through the stimulation of the myocardial ARs. The results of the present study, in fact, indicate a major role of ␤ARs in ␤ARK1 upregulation, because the chronic stimulation of ␣ 1 ARs does not induce any change in cardiac ␤ARK1 content. The selective increase of ␤ARK1 only in the presence of ISOinduced hypertrophy, but not in PE-induced hypertrophy, also rules out the possibility that hypertrophy per se increases ␤ARK1.
The mechanisms of PE-and ISO-induced cardiac hypertrophy are not completely understood. We know that in isolated neonatal cardiac myocytes treatment with PE or ISO leads to the activation of different nuclear factors, which results in increased myocardial protein synthesis. 14 However, in vivo PE treatment can induce a temporary increase in blood pressure, thus simulating a model of cardiac hypertrophy caused by pressure overload. Differences in the hemodynamic effects induced by ISO and PE might be responsible for the differential regulation of ␤ARK1 observed, rather than the chronic activation of cardiac ␤-and ␣ 1 ARs. To rule out this possibility, we added two controls to our experimental design. First, we used a transgenic mouse model of ␣ 1 ARinduced myocardial hypertrophy (CAM-␣ 1B AR). 15 In this model, cardiac hypertrophy develops because of the direct activation of the cardiac ␣ 1 AR signaling pathway in the absence of changes in blood pressure. 15 We observed no changes in the cardiac content of ␤ARK1 of these transgenic animals, further strengthening our conclusion that chronic ␣ 1 AR stimulation does not induce changes in the expression of cardiac ␤ARK1. Second, we examined ␤ARK1 levels in isolated adult rat myocytes treated for 24 hours with ISO or PE. In these studies, we demonstrated conclusively that only the direct action of ␤AR stimulation causes enhanced ␤ARK1 expression, because ␣ 1 AR signaling did not alter myocyte ␤ARK1 levels.
␤ARK1 upregulation was observed in several pathophysiological conditions, such as heart failure, 9 ischemia, 7 hypertension, 8 and myocardial hypertrophy. 4 All those conditions are characterized by adrenergic activation, 10, 11 by early impairment of the ␤AR signaling pathway, 3,19 -21 and by the eventual development of heart failure. 22, 23 Thus, the results of the present study add new information to this scenario, showing that the chronic and selective activation of ␤ARs results in the worsening of ␤AR signaling through the increase in myocardial ␤ARK1 levels and activity. We have demonstrated that the increase in ␤ARK1 expression arises independently from the general development of cardiac hypertrophy. Thus, ␤ARK1 appears to play a pivotal role in the regulation of contractility in the heart, and the selective and chronic activation of ␤ARs is the mechanism that triggers ␤ARK1 upregulation in apparently all conditions where the SNS is activated.
In ISO-induced hypertrophy, increased ␤ARK1 expression and activity resulted in the impairment of ␤AR signaling. This result confirms the central role of ␤ARK1 in the regulation of ␤AR signaling observed in transgenic mice overexpressing ␤ARK1 or a ␤ARK1 peptide inhibitor and also in ␤ARK1 heterozygous knockout animals. 5, 6 The absence of the upregulation of ␤ARK1 in PE-treated mice can explain why the ␤AR responsiveness in these mice was not blunted as in the ISO-treated group. Baseline membrane adenylyl cyclase activity, however, was reduced in PE-treated animals, which suggests that changes are occurring in myocardial adenylyl cyclase signaling. In rat models of hypertension and hypertrophy an increase in the myocardial G␣i content was observed. 3, 24 Thus, we examined G␣i in PEtreated versus control mouse hearts and did find a significant increase, suggesting that this could be responsible for the reduction of cardiac adenylyl cyclase activity seen in this model. We previously found no change in myocardial G␣i expression in pressure overload ventricular hypertrophy 4 demonstrating that Gi and ␤ARK1 can both be differentially regulated depending on the hypertrophy stimulus.
In conclusion, this study shows that in catecholamineinduced cardiac hypertrophy the observed increase in cardiac ␤ARK1 content is due to the chronic activation of ␤ARs but not ␣ 1 ARs. This may represent the mechanism that triggers the increase in ␤ARK1 content observed in pressure overload hypertrophy as well as in other pathophysiological conditions associated with adrenergic activation, such as heart failure and ischemia. Thus, targeted inhibition of myocardial ␤ARK1 activity may be a novel therapeutic approach for preventing dysfunctional ␤AR signaling. 
